A Phase 1 Study to Explore the Cardiac Pharmacodynamics of MT-1303

Inclusion Criteria: * Healthy and free from clinically significant illness or disease. * Male and female subjects of non-childbearing potential aged 18 to 55 years. * Normal or non-clinically significant 12-lead ECG. * Holter recording with no clinically significant abnormalities. * Systolic blood pressure: 90 to 140 mmHg, diastolic blood pressure: 50 to 90 mmHg Exclusion Criteria: * A History of severe adverse reaction or allergy to any medical product. * Clinically significant endocrine, thyroid, hepatic, respiratory, gastrointestinal, renal, cardiovascular disease, eye disorder or history of psychiatric/psychotic disorder. * A history of tuberculosis. * Have a positive HBsAg, HBcAb, HCVAb or HIV-1 and HIV-2 test. * Previously having received MT-1303, fingolimod, or any other sphingosine-1-phosphate receptor modulators. * Clinical relevant abnormal medical history, or physical findings or laboratory values. * Clinically significant 12-lead ECG abnormalities. * Clinical relevant abnormal findings in echocardiograph.